Trials / Completed
CompletedNCT00503022
Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular Degeneration
A Randomized, Double-Masked, Multi-Center Phase I Study of 6 Months Duration to Assess the Safety and Tolerability of Intravenous ACZ885 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- —
Summary
This study evaluates the tolerability and safety of a single intravenous infusion of ACZ885. It also explores the efficacy of the compound in central macular edema and visual acuity in patients with wet age-related macular edema.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACZ885 |
Timeline
- Start date
- 2006-07-01
- First posted
- 2007-07-18
- Last updated
- 2007-12-28
Locations
8 sites across 2 countries: Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT00503022. Inclusion in this directory is not an endorsement.